Ultragenyx Pharmaceutical Inc.
RARE
$39.34
$0.090.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -569.18M | -558.99M | -585.12M | -613.35M | -606.64M |
| Total Depreciation and Amortization | 35.54M | 34.68M | 33.12M | 29.62M | 26.01M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 105.53M | 101.25M | 106.09M | 107.83M | 120.93M |
| Change in Net Operating Assets | 13.92M | 4.47M | -23.56M | -32.76M | -15.10M |
| Cash from Operations | -414.19M | -418.59M | -469.47M | -508.67M | -474.81M |
| Capital Expenditure | -7.49M | -8.44M | -10.52M | -22.44M | -44.27M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -10.28M | -219.08M | 122.79M | 173.58M | 212.27M |
| Cash from Investing | -17.77M | -227.52M | 112.28M | 151.13M | 168.00M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 392.24M | 719.67M | 740.73M | 388.17M | 388.17M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 7.00M | 7.00M | 0.00 | 636.00K | -28.00K |
| Cash from Financing | 399.24M | 726.67M | 740.73M | 388.81M | 388.14M |
| Foreign Exchange rate Adjustments | -2.53M | 1.05M | -940.00K | -428.00K | 462.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -35.24M | 81.61M | 382.59M | 30.84M | 81.80M |
